type here...

CATEGORIES

Medication

LATEST

1234Page 3 of 4

TRENDING

EDITORS CHOICE

Is the New York Times a Shill for Promoters of Psychedelics?

James Coyne -
Evidence that the newspaper is not sufficiently detached from promoters to provide an open-minded but skeptical perspective that readers should be able to expect.

Depression isn’t Caused by Low Serotonin Level, Are SSRIs still Effective?

Isabella Soerjanto MD -
Several previous studies have concluded that SSRIs can significantly reduce the risk of depression. However, a recent study refutes this.

First Drug Synthesized by AI Goes into Clinical Trials

Dr Sohail Merchant -
If all goes well, thanks to artificial intelligence, we may soon have a new AI-synthesized drug capable of assisting OCD patients in managing their symptoms and thus leading normal lives.

Achieve Life Sciences Announces Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Medika Life -
Clinical results in primary and secondary endpoints for 6- and 12-week experimental smoking cessation treatment reported by company sponsor.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories